Clinical Trials Logo

Clinical Trial Summary

This is a prospective cohort study exploring a broadened use of ulipristal acetate as a cervical preparation agent for second trimester surgical abortion. Specifically, this pilot study will test the feasibility of using ulipristal as a pharmacologic cervical preparation with adjunct misoprostol prior to surgical abortion.


Clinical Trial Description

Second trimester abortion comprises <10% of all induced abortions in the United States but there is still an important need to provide this service to women. Prior to dilation and evacuation (D&E), adequate preparation of the uterine cervix is an important part of preventing complications of the procedure. Commonly, this is done using osmotic dilators that are placed into the uterine cervix but cervical preparation can also be achieved using medications alone. Mifepristone is commonly used for this purpose but its use is regulated and often restricted due to the REMS (Risk Evaluation and Mitigation Strategy) program. The objective of this pilot study is to test the feasibility of using ulipristal, an oral medication similar to Mifepristone, as a medical form of cervical preparation prior to surgical abortion.This is a prospective cohort study investigating the use of ulipristal acetate (UPA) for pharmacologic cervical preparation with adjunct misoprostol prior to second trimester surgical abortion among women who are 16 to 18 6/7 weeks gestational age. Due the mechanism of action of UPA as a selective progesterone receptor modulator (SPRM) being similar to that of mifepristone, a medication known to be effective for cervical preparation, the investigators seek to describe the use of another SPRM for this same purpose. The investigators will conduct a pilot study assessing the feasibility of using UPA for cervical priming and report descriptive measures of its use. Per clinic protocols, patients over 16-weeks gestation attend a consult and cervical preparation appointment the day prior to their procedure. Eligible patients will be offered enrollment. Subjects will receive UPA 90mg one day prior to their procedure and no osmotic dilators. All subjects will receive pre-procedure misoprostol (600mcg 90 minutes prior to procedure). The investigators will observe patients through their planned procedure and report descriptive measures of its use. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03802149
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Early Phase 1
Start date April 16, 2019
Completion date April 2, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05326854 - NAVIGATION ASSISTED CARE PROGRAM AND TERMINATION OF PREGNANCY N/A
Completed NCT04602052 - Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 Weeks of Gestation in Ethiopia N/A
Completed NCT00994734 - Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion N/A
Not yet recruiting NCT04303949 - Multi-Media E-Book for Second‐Trimester Termination Due to Fetal Anomaly N/A
Completed NCT04910958 - Impact of COVID-19 Pandemic on Early Spontaneous Abortions and Early Termination of Pregnancy
Completed NCT03393455 - Obstetric & Pediatric Evolution Following Parental Refusal for Early Termination of Pregnancy Despite Fetal Risk
Completed NCT03877900 - A Feasibility Study of Virtopsy With Tissue Sampling in Besancon University Hospital
Completed NCT02597699 - Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide Phase 3
Enrolling by invitation NCT03494842 - TENS for Suction Evacuation for Termination of 1st Trimester Pregnancies N/A
Completed NCT01811056 - Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion N/A